Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Boilerplate filing disclaimer; no substantive company event disclosed in the provided Item 8.01 text.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Boilerplate filing disclaimer; no substantive company event disclosed in the provided Item 8.01 text
- No investor-actionable information on operations, financing, litigation, or strategic developments
Item EX-99.1 · Exhibit EX-99.1
- New SNDX-4321 expands pipeline into EGFR-mutated NSCLC, targeting L858R, CNS metastases, atypical mutations, and acquired resistance
- IND for SNDX-4321 expected by end-2026, with Phase 1 initiation planned for 2027
- SNDX-62122 advances wholly owned next-generation menin inhibitor program into myelofibrosis, with IND and Phase 1 planned for 2027
- Revumenib Phase 1/2 myelofibrosis proof-of-principle trial expected to begin 4Q26, with initial data targeted for 2H27
- Axatilimab Phase 2 idiopathic pulmonary fibrosis topline data remain on track for 4Q26, providing a near-term pipeline catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.